Vericel to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
July 06 2016 - 4:30PM
Vericel Corporation (Nasdaq:VCEL), a leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced that Nick
Colangelo, president and CEO, and Gerard Michel, chief financial
officer and vice president of corporate development, will present
at the Cantor Fitzgerald 2nd Annual Healthcare
Conference
at Le Parker Meridien in New York
City, NY on Tuesday, July 12, 2016, at 8:30am Eastern time.
The presentation will be webcast live and may be accessed from
the news and events section of the Vericel
website: http://wsw.com/webcast/cantor4/vcel.
About Vericel Corporation
Vericel Corporation is a leader in developing patient-specific
expanded cellular therapies for use in the treatment of patients
with severe diseases and conditions. The company markets two
autologous cell therapy products in the United States: Carticel®
(autologous cultured chondrocytes), an autologous chondrocyte
implant for the treatment of cartilage defects in the knee, and
Epicel® (cultured epidermal autografts), a permanent skin
replacement for the treatment of patients with deep-dermal or
full-thickness burns comprising greater than or equal to 30 percent
of total body surface area. Vericel is also developing MACI™, a
third-generation autologous chondrocyte implant for the treatment
of cartilage defects in the knee, and ixmyelocel-T, a
patient-specific multicellular therapy for the treatment of
advanced heart failure due to ischemic dilated
cardiomyopathy. For more information, please visit the
company's website at www.vcel.com.
CONTACT:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
or
Lee Stern
The Trout Group
lstern@troutgroup.com
(646) 378-2922
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024